Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

Share Price is delayed by 15 minutes
Get Live Data
33.30    -0.40 (-1.19%)
Bid:
33.50
Ask:
34.30
Spread: 0.80 (2.388%)
Market Cap: £24.45m
CAR Live PriceLast checked at - London Stock Exchange

Intraday Carclo Share Chart

Full Year Trading Statement and COVID-19 Update

4 May 2020 07:00

RNS Number : 7390L
Carclo plc
04 May 2020
 

Carclo plc

("Carclo" or "the Group" or "the Company")

 

Full Year Trading Statement and COVID-19 Update

 

Trading update for the year ended 31 March 2020 ("FY2020")

 

The Board is pleased to announce that trading for the continuing businesses during the second half of FY2020 reflected a continuation of the positive momentum seen in the first half of the year. Consequently, the Board expects to report, subject to audit, underlying results for the continuing businesses for FY2020 in line with its expectations.

 

The Technical Plastics Division performed strongly for the year as a whole, largely driven by increased volume as the business continued to secure a number of new programmes in its core medical market. The Aerospace Division also performed well, driven by increased volumes of spares orders and customers building inventory ahead of the UK's exit from the EU.

 

As previously announced, the Group successfully completed the exit from the loss-making businesses of the LED Division in December 2019.

 

The Group's net debt (including IFRS16 leases and subject to audit) at 31 March 2020 was £25.8m, (30 September 2019: £31.7m).

 

Impact of COVID-19

 

Whilst the initial outbreak of COVID-19 had limited impact on trading in final quarter of FY2020, disruption has been more extensive in the first quarter of the current financial year. During this period, the Group's primary focus has been to ensure the wellbeing of staff and the continued safe operation of its businesses. All applicable government advice has been followed across the different countries in which the Group operates. Pleasingly, it has been possible to keep most sites operational through the lockdown period, enabling the Group to continue to serve its customers many of whom operate in essential industries, particularly the medical diagnostic sector.

 

Given the division's focus on the medical market, overall demand across the Technical Plastics business has remained relatively resilient, with a number of its products being used directly in COVID-19 testing applications. Notwithstanding continued demand, the implementation of governmental guidance on social distancing and some limited shutdowns have impacted efficiency and throughput across the Group, which will inevitably have a negative impact on profitability. 

 

Demand for the Aerospace business has been significantly impacted by the downturn in the aerospace sector.

 

Management has already taken action to mitigate these challenges, including accessing government support programmes where available and a reduction in variable costs where appropriate. The Board has taken a 20% cut in fees and salaries for the first quarter of the new financial year. The Group remains focused on ensuring operational continuity where it can; however, it remains very difficult to predict how the ongoing crisis will affect performance going forward. 

 

Outlook

Given the current levels of uncertainty it is not possible for the Board to provide near-term guidance on expected financial performance. As previously reported, discussions continue with the Group's lending bank and pension trustees in order to agree a long-term financing position for Carclo. Whilst these negotiations remain ongoing, there can be no certainty that a satisfactory and affordable agreement will be reached. The Group will make further announcements as appropriate.

Timing of full year results

 

Mindful of the ongoing uncertainty presented by the COVID-19 situation, and the guidance from the Financial Conduct Authority that public companies should consider delaying preliminary announcements, the Board has decided to delay the publication of the Company's Full Year Results for the year ended 31 March 2020 beyond 30 June 2020, the date on which Carclo had previously expected to announce. The revised publication date will be published in due course.

 

Rights attaching to listed equity shares

In compliance with Listing Rule 9.2.6ER(1), the Company has forwarded to the FCA for publication a copy of its Articles of Association, which is the document that sets out the terms and conditions on which its listed equity shares were issued.

A copy of the Articles of Association have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

 

 

About Carclo plcCarclo plc is a public company whose shares are quoted on the Main Market of the London Stock Exchange. The Group is a global provider of value-adding engineered solutions for the medical, optical and aerospace industries.

 

 

Enquiries:

Carclo plc 01924 268040

Matt Durkin-Jones - Chief Financial Officer

 

FTI Consulting 020 3727 1340

Nick Hasell / Susanne Yule

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKZGGKNFZGGZM
Date   Source Headline
29th Apr 20264:59 pmRNSDirector Dealing – Late Notification
27th Apr 20267:00 amRNSHolding(s) in Company
23rd Apr 202610:34 amRNSHolding(s) in Company
23rd Apr 20267:00 amRNSTrading Update
24th Dec 202510:10 amRNSDirector/PDMR Shareholding
24th Dec 202510:10 amRNSDirector/PDMR Shareholding
25th Nov 20257:00 amRNSDirector/PDMR Shareholding
21st Nov 20257:00 amRNSHalf-year Financial Report
17th Nov 20257:00 amRNSNotice of Half Year Results
30th Sep 20256:20 pmRNSDirector/PDMR Shareholding
30th Sep 20256:14 pmRNSDirector/PDMR Shareholding
26th Sep 202512:30 pmRNSResult of AGM
26th Sep 20257:00 amRNSTrading Update
19th Sep 20255:58 pmRNSDirector/PDMR Shareholding
17th Sep 20257:00 amRNSChange of Auditor
11th Sep 20258:41 amRNSDirector/PDMR Shareholding
1st Sep 20257:30 amRNSRestoration - Carclo PLC
29th Aug 202511:55 amRNSNotice of AGM
29th Aug 20257:00 amRNSFull Year 2025 audited results
28th Aug 20257:00 amRNSNotice of Results and Investor Presentation
1st Aug 20257:30 amRNSSuspension - Carclo PLC
17th Jul 20254:42 pmRNSHolding(s) in Company
15th Jul 20257:00 amRNSContract renewal strengthens revenue visibility
10th Jul 20257:00 amRNSTrading Statement & Delay in 2025 Audited Results
2nd May 202511:33 amRNSHolding(s) in Company
30th Apr 20257:00 amRNSTrading Statement
28th Apr 20255:06 pmRNSHolding(s) in Company
24th Apr 20254:02 pmRNSRefinancing Arrangements, Pension Scheme Valuation
3rd Apr 20257:00 amRNSHolding(s) in Company
6th Mar 202510:43 amRNSHolding(s) in Company
18th Feb 20255:10 pmRNSHolding(s) in Company
13th Feb 20257:00 amRNSCFO Appointment
19th Dec 20243:49 pmRNSHolding(s) in Company
5th Dec 20247:00 amRNSInterim Report and Accounts 30 September 2024
12th Nov 202411:11 amRNSNotice of Interim Results & Investor Presentation
10th Sep 20249:33 amRNSHolding(s) in Company
5th Sep 20241:30 pmRNSResult of AGM
5th Sep 20247:00 amRNSTrading Update
16th Aug 202412:32 pmRNSHolding(s) in Company
5th Aug 202412:11 pmRNSHolding(s) in Company
31st Jul 202410:00 amRNS2024 Annual Report & Accounts and Notice of AGM
30th Jul 20243:21 pmRNSHolding(s) in Company
24th Jul 20242:49 pmRNSHolding(s) in Company
24th Jul 202412:57 pmRNSHolding(s) in Company
23rd Jul 20243:48 pmRNSHolding(s) in Company
23rd Jul 20241:08 pmRNSDirector/PDMR Shareholding
18th Jul 20247:00 amRNSFinal Results
17th Jul 20241:07 pmRNSHolding(s) in Company
16th Jul 20247:00 amRNSNotice of Results
8th Jul 20248:51 amRNSBank Facilities Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.